IVERMECTIN — 3 mg, 6 mg, 12 mg tablets
Antiparasitic (anthelmintic) • strongyloidiasis • onchocerciasis • scabies/lice (region-dependent)
Educational content only. Ivermectin is used for specific parasitic infections; product availability, approved indications, and prescription status differ by country. Always follow local approved labeling and clinician guidance.
🔎 Quick Links
📦 Product Snapshot
Active substanceIvermectin
Common oral strengths3 mg, 6 mg, 12 mg tablets (country/brand dependent)
Dosage formOral tablets; topical forms exist in some markets (e.g., for rosacea or lice)
Oral dosing is typically weight-based (micrograms per kg) and depends on the parasite and local labeling. Do not self-treat—confirm diagnosis and regimen with a clinician.
Reference brand (oral)STROMECTOL® (ivermectin)
Primary evidence-based usesOnchocerciasis and intestinal strongyloidiasis (widely recognized in clinical guidance)
How it works (simplified)Interferes with parasite nerve/muscle function → paralysis and death of susceptible parasites
Clinical recommendations differ by region and co-endemic parasites (notably Loa loa). Screening strategies may be required before mass or presumptive treatment.
Request verified information
Use our inquiry form to request official leaflet links, verify strengths, and ask general packaging/authenticity questions. We do not provide medical advice.
International visitors: informational support and inquiries are available to users in the United States, United Kingdom, and Australia.
Parasite-specific • weight-based dosing • check drug interactions • avoid self-medication
🧠 Overview
Ivermectin is a broad-spectrum antiparasitic medicine used for selected helminth (worm) and ectoparasite conditions. Oral ivermectin is widely referenced in
clinical guidance for onchocerciasis (river blindness) and strongyloidiasis, and topical ivermectin products are approved in some markets for
conditions such as rosacea or head lice.
Mechanism (practical summary): ivermectin increases chloride ion influx in susceptible parasites by interacting with ligand-gated ion channels,
leading to paralysis and death of the parasite. Human CNS exposure is normally limited by the blood-brain barrier; however, neurologic adverse events can occur,
especially with overdose or specific risk factors.
Clinical positioning: ivermectin regimens are parasite-specific, often weight-based, and may require repeat dosing or follow-up testing depending on the infection.
In regions where Loa loa is endemic, special screening/strategy may be needed due to risk of severe reactions in individuals with high microfilarial loads.
🏷️ Brand & Manufacturer Examples
Examples only — always verify the exact manufacturer, batch, and local approval status.
| Market / Type | Brand example | Typical strengths | Notes |
|---|---|---|---|
| Reference brand (oral) | STROMECTOL® | 3 mg tablets (US labeling) | Indications include strongyloidiasis and onchocerciasis per FDA consumer/label information. |
| India (example) | Iverheal® (Healing Pharma) | 6 mg / 12 mg (varies by pack) | Example of an Indian-market brand; verify local approvals/availability and exact labeling. |
| Topical (region-dependent) | Ivermectin topical (various) | Cream/lotion strengths vary | Approved topical uses differ by country (e.g., rosacea or lice). Confirm the specific product and indication. |
Tip: for authenticity checks, compare on-pack manufacturer name/address, batch/lot, MFG/EXP dates, and any verification/serialization features used in your region.
⚠️ Safety, Side Effects & Monitoring
Common adverse effects (oral; may vary by indication)
- Headache, dizziness, fatigue/somnolence
- Nausea, abdominal discomfort, diarrhea
- Skin itching/rash (may relate to parasite die-off and immune response)
Some reactions in onchocerciasis are driven by inflammatory response to dying microfilariae (Mazzotti-type reactions); clinical supervision may be needed.
Serious risks & red flags
• Neurologic toxicity: confusion, ataxia, tremor, seizures (rare; seek urgent care).
• Severe reactions in Loa loa co-infection: risk increases with high microfilarial loads; screening/strategy may be required in endemic areas.
• Severe skin reactions / hypersensitivity: stop and seek care if widespread rash, blistering, facial swelling, or breathing difficulty occurs.
• Severe reactions in Loa loa co-infection: risk increases with high microfilarial loads; screening/strategy may be required in endemic areas.
• Severe skin reactions / hypersensitivity: stop and seek care if widespread rash, blistering, facial swelling, or breathing difficulty occurs.
⛔ Contraindications / cautions (general)
- Hypersensitivity to ivermectin or formulation components.
- Pregnancy / breastfeeding: risk-benefit assessment depends on indication and local guidance.
- Liver disease or significant comorbidity: may warrant closer monitoring.
- Children: eligibility and dosing are strictly weight- and guideline-dependent.
⚕️ Notable interaction considerations
- Warfarin/anticoagulants: case reports of INR changes exist; monitor INR if used together.
- Other CNS-active drugs/alcohol: additive dizziness/somnolence may occur.
- Polypharmacy: always reconcile current meds/supplements with a clinician before treatment.
Typical regimen formats (for clinician-led care)
- Strongyloidiasis: commonly weight-based oral dosing; follow-up testing may be recommended.
- Onchocerciasis: typically repeated community/individual dosing schedules; ivermectin targets microfilariae (not adult worms).
- Other uses: may be topical or oral depending on region and indication; confirm what is actually approved locally.
❓ FAQ
FAQ #1: What infections is ivermectin actually used for?
Oral ivermectin is commonly referenced for intestinal strongyloidiasis and onchocerciasis in clinical guidance. Some topical forms are approved in certain countries for conditions such as rosacea or head lice. Always confirm local approved indications.
FAQ #2: Is dosing the same for every condition?
No. Ivermectin dosing is parasite-specific and often weight-based. Some regimens require repeat doses and follow-up testing. Do not copy a regimen from another condition.
FAQ #3: Why is Loa loa mentioned as a special risk?
In certain Central/West African regions, Loa loa can co-exist with onchocerciasis. People with high Loa loa microfilarial loads have a higher risk of severe adverse events when treated with ivermectin. Screening and adapted strategies may be required.
FAQ #4: What are the main side effects to watch for?
Common effects include dizziness, headache, nausea, and rash/itching. Seek urgent care for severe rash, swelling, breathing problems, or neurologic symptoms (confusion, seizures).
FAQ #5: Do I need tests after treatment?
For some infections (e.g., strongyloidiasis), follow-up testing may be advised to confirm clearance—especially if symptoms persist or if the patient is immunosuppressed. Your clinician will advise the correct schedule.
📚 Official References
- U.S. FDA — Ivermectin overview (approved human uses and formulations)
- FDA label (PDF) — STROMECTOL® (ivermectin)
- CDC — Clinical Care of Strongyloides
- CDC — Clinical Treatment of Onchocerciasis
- WHO — Onchocerciasis fact sheet (Loa loa co-endemic considerations)
- Healing Pharma (India) — Iverheal product page (brand example)